CANCER RESEARCH - Texas A&M University (TAMU) Scholar

publication venue for

Abstract 1858: Rb deficient HPV+ HNSCC experienced enhanced sensitivity to aurora kinase inhibitors by altering the balance of MAD2 and TRIP13 levels. 82:1858-1858. 2022
Abstract 236: Nuclear receptor 4A1 ligands target T-cell exhaustion in colorectal cancer. 82:236-236. 2022
Abstract 819: ERBB4 mediates IL10-induced growth of EGFR-independent colon tumors. 82:819-819. 2022
Abstract GS1-09: Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells. 82:gs1-09-gs1-09. 2022
Abstract 410: Development of novel, non-toxic rifamycins that reverse drug resistance. 82:410-410. 2022
Abstract 2106: Combined deacetylase and bromodomain inhibition downregulates ERCC2 and suppresses growth of metastatic colon cancer cells. 81:2106-2106. 2021
Abstract 368: Aurora kinase inhibitors cause cell death in HPV+ cells: A plausible treatment option for HPV+ cancers. 81:368-368. 2021
Abstract 369: Identification of pathways that enhance cell death in NOTCH1-mutant HNSCC. 81:369-369. 2021
Transient Activation of the Hedgehog-Gli Pathway Rescues Radiotherapy-Induced Dry Mouth via Recovering Salivary Gland Resident Macrophages.. 80:5531-5542. 2020
A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.. 80:1011-1023. 2020
Abstract P3-03-08: Identification of drugs that induce the death or suppress the growth of p53-mutant breast cancer. 80:p3-03-08-p3-03-08. 2020
Abstract 1662: In vivo drug response evaluation in anaplastic thyroid cancer patient-derived tumor xenografts following high-throughput screening. 80:1662-1662. 2020
Abstract A10: Fusobacteria upregulates PD-L1 in head and neck cancer cell lines: Potential mechanism for immune evasion. 80:A10-A10. 2020
Abstract 2614: CCAR2 acetylation establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition. 79:2614-2614. 2019
Abstract 4669: Overcoming therapy resistance in stem cell-rich triple negative breast cancer through p38 MAP kinase inhibition. 79:4669-4669. 2019
Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.. 79:918-927. 2019
Abstract 2824: Modulation of oral cancer cells survival and invasiveness by fusobacteria. 79:2824-2824. 2019
Abstract LB-320: PPTC testing of an OLIG2 inhibitor CT-179 in patient-derived orthotopic xenograft mouse models of pediatric GBM. 79:lb-320-lb-320. 2019
Long-Chain n-3 Fatty Acids Attenuate Oncogenic KRas-Driven Proliferation by Altering Plasma Membrane Nanoscale Proteolipid Composition.. 78:3899-3912. 2018
SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma.. 78:3135-3146. 2018
Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer.. 78:4459-4470. 2018
Abstract 2945: Arsenic trioxide sensitizes glioma stem cells to brain penetrant PI3K and mTOR inhibitor GDC-0084. 78:2945-2945. 2018
Abstract 4819: High-throughput screening of glioma stem-like cells (GSCs) identifies synergistic therapeutic combination of FGFR inhibitor and CDK4/6 inhibitor. 78:4819-4819. 2018
Abstract 5139: F. nucleatum induces invasive phenotypes in oral cancer cells in vitro. 78:5139-5139. 2018
Abstract LB-041: Establishment and characterization of patient derived orthotopic xenograft mouse models representing a serial of primary and recurrent pediatric brain tumors. 78:lb-041-lb-041. 2018
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.. 77:5313-5326. 2017
Abstract 2229: Prevention by tolfenamic acid and characterization of the molecular targets in Pirc and FAP colorectal adenomas. 77:2229-2229. 2017
Abstract 576: Neoadjuvant immunotherapy improves efficacy of image-guided thermal ablation to generate curative responses in a murine breast cancer model. 77:576-576. 2017
PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.. 77:732-741. 2017
Abstract 1244: An in vitro biological assay to identify small molecule upregulators of let-7 miRNA in LIN28- positive ovarian cancer cells. 77:1244-1244. 2017
Abstract 4214: Identification of personalized active agents in pediatric gliomas through high-throughput drug screening in matching pairs of patient derived orthotopic xenograft (PDOX) neurosphere and monolayer cells. 77:4214-4214. 2017
Abstract 839: Novel polypectomy system in a preclinical model of colon cancer. 76:839-839. 2016
Targeted Deletion of p53 in Lgr5-Expressing Intestinal Stem Cells Promotes Colon Tumorigenesis in a Preclinical Model of Colitis-Associated Cancer.. 75:5392-5397. 2015
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.. 75:1035-1045. 2015
Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.. 5184-5194. 2014
The NADH oxidase ENOX1, a critical mediator of endothelial cell radiosensitization, is crucial for vascular development.. 74:38-43. 2014
Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.. 73:6164-6174. 2013
The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.. 73:3997-4008. 2013
FGFR1 is essential for prostate cancer progression and metastasis.. 73:3716-3724. 2013
FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.. 73:1981-1992. 2013
Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and -catenin.. 5473-5484. 2013
Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer.. 72:6490-6501. 2012
In vivo diagnosis of melanoma and nonmelanoma skin cancer using oblique incidence diffuse reflectance spectrometry.. 72:2738-2745. 2012
Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors.. 72:1485-1493. 2012
Abstract 4007: Different expression of AHCYL1 affecting ovarian carcinogenesis between chickens and women. 4007-4007. 2012
Autophagy enhanced by microtubule- and mitochondrion-associated MAP1S suppresses genome instability and hepatocarcinogenesis.. 71:7537-7546. 2011
In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.. 71:4742-4747. 2011
Abstract 2729: Proteomic analysis reveals a network of inflammatory genes in epidermis associated with skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice. 71:2729-2729. 2011
Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth.. 71:2466-2475. 2011
Shmt1 heterozygosity impairs folate-dependent thymidylate synthesis capacity and modifies risk of Apc(min)-mediated intestinal cancer risk.. 71:2098-2107. 2011
Abstract 1379: High throughput screening to identify molecules that alter VHL stability. 71:1379-1379. 2011
Integrated microRNA and mRNA expression profiling in a rat colon carcinogenesis model: Effect of a chemoprotective diet. 71:1160-1160. 2011
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.. 70:8329-8338. 2010
Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth.. 70:6824-6836. 2010
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.. 70:4949-4960. 2010
Abstract 582: Targeting the blood-brain barrier with a non-canonical iron-mimicry mechanism: A translational approach for the detection and treatment of human brain tumors. 70:582-582. 2010
Abstract P4-06-06: Singleminded-2s (Sim2s) Promotes Breast Tumor Cell Differentiation and Inhibits Metastasis in MCF10DCIS.COM Cells. p4-06-06-p4-06-06. 2010
Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells.. 69:3405-3414. 2009
Leptin enhances cholangiocarcinoma cell growth.. 68:6752-6761. 2008
Curcumin decreases specificity protein expression in bladder cancer cells.. 68:5345-5354. 2008
Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.. 68:3495-3504. 2008
Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice.. 68:3985-3991. 2008
Serotonin Metabolism Is Dysregulated in Cholangiocarcinoma, which Has Implications for Tumor Growth. 68:9184-9193. 2008
Flat colorectal cancers are genetically determined and progress to invasion without going through a polypoid stage.. 67:11594-11600. 2007
Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway.. 67:10782-10788. 2007
The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells.. 67:11001-11011. 2007
The let-7 microRNA represses cell proliferation pathways in human cells.. 67:7713-7722. 2007
Docosahexaenoic acid and butyrate synergistically induce colonocyte apoptosis by enhancing mitochondrial Ca2+ accumulation.. 67:5561-5568. 2007
Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells.. 67:3286-3294. 2007
Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors.. 67:2816-2823. 2007
Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.. 67:289-299. 2007
Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways.. 67:674-683. 2007
Activation of human long interspersed nuclear element 1 retrotransposition by benzo(a)pyrene, an ubiquitous environmental carcinogen.. 66:2616-2620. 2006
3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha.. 66:2459-2467. 2006
Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis.. 66:1481-1490. 2006
In utero exposure of mice to dibenzo[a,l]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor.. 66:755-762. 2006
Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists.. 66:412-418. 2006
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.. 65:11478-11485. 2005
Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.. 65:11001-11009. 2005
gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway.. 65:11437-11446. 2005
Mechanism of cell cycle regulation by FIP200 in human breast cancer cells.. 65:6676-6684. 2005
Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene.. 65:6534-6542. 2005
Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.. 65:5778-5784. 2005
A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia.. 65:2890-2898. 2005
Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis.. 65:887-897. 2005
Erratum: Nuclear factor-B is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma (Cancer Research (September 2004) 64 (6511-6523). 64:8130. 2004
1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells.. 64:5994-6001. 2004
Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat.. 64:6797-6804. 2004
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma.. 64:6511-6523. 2004
Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells.. 64:6740-6749. 2004
A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.. 64:5767-5774. 2004
Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors.. 64:4555-4562. 2004
Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha.. 64:2889-2897. 2004
Expression of base excision DNA repair genes is a sensitive biomarker for in vivo detection of chemical-induced chronic oxidative stress: identification of the molecular source of radicals responsible for DNA damage by peroxisome proliferators.. 64:1050-1057. 2004
Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate.. 63:8784-8790. 2003
Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors.. 63:4936-4944. 2003
Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin.. 63:1254-1261. 2003
Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.. 63:958-964. 2003
Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.. 63:60-66. 2003
Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.. 62:5571-5579. 2002
Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.. 62:2313-2317. 2002
Fibroblast growth factor receptor 1 phosphotyrosine 766: molecular target for prevention of progression of prostate tumors to malignancy.. 62:1898-1903. 2002
p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction.. 61:6899-6905. 2001
A rare premalignant prostate tumor epithelial cell syndecan-1 forms a fibroblast growth factor-binding complex with progression-promoting ectopic fibroblast growth factor receptor 1.. 61:5295-5302. 2001
Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.. 61:3902-3907. 2001
Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity.. 61:1100-1106. 2001
Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis.. 61:1138-1143. 2001
Modulation of tumor angiogenesis by stem cell factor.. 60:6757-6762. 2000
Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators.. 60:4798-4803. 2000
Genomic structure, chromosomal mapping, and promoter region analysis of murine uridine phosphorylase gene.. 59:4997-5001. 1999
Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium.. 59:3090-3099. 1999
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.. 59:336-341. 1999
High frequency of beta-catenin (ctnnb1) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat.. 58:1127-1129. 1998
Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells.. 57:5369-5378. 1997
Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid.. 57:3424-3428. 1997
Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras.. 57:3180-3188. 1997
A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice.. 57:162-168. 1997
Inhibition of apoptosis in colon tumors induced in the rat by 2-amino-3-methylimidazo[4,5-f]quinoline.. 56:4307-4310. 1996
Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice.. 55:3183-3191. 1995
Dietary fat, fiber, and carcinogen alter fecal diacylglycerol composition and mass.. 55:2293-2298. 1995
Anticarcinogenic activity of indole-3-carbinol acid products: ultrasensitive bioassay by trout embryo microinjection.. 54:3617-3619. 1994
Sequence-specific interaction of a conformational domain of p53 with DNA.. 53:5361-5364. 1993
Characterization of the aryl hydrocarbon receptor and aryl hydrocarbon responsiveness in human ovarian carcinoma cell lines.. 53:1802-1807. 1993
Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1.. 51:5304-5307. 1991
Promotion of aflatoxin B1 carcinogenesis by the natural tumor modulator indole-3-carbinol: influence of dose, duration, and intermittent exposure on indole-3-carbinol promotional potency.. 51:2362-2365. 1991
Rat ovarian granulosa cell culture: a model system for the study of cell-cell communication during multistep transformation.. 51:696-706. 1991
Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds on the occupied nuclear estrogen receptor in MCF-7 human breast cancer cells.. 50:3579-3584. 1990
Linoleic acid metabolism in metastatic and nonmetastatic murine mammary tumor cells.. 49:4724-4728. 1989
Structure-dependent induction of aryl hydrocarbon hydroxylase in human breast cancer cell lines and characterization of the Ah receptor.. 49:4531-4535. 1989
Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck.. 49:1130-1137. 1989
Gene for ovarian granulosa cell tumor susceptibility, Gct, in SWXJ recombinant inbred strains of mice revealed by dehydroepiandrosterone.. 48:5092-5095. 1988
Quantitative structure-activity relationships: analysis of interactions of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2-substituted analogues with rat, mouse, guinea pig, and hamster cytosolic receptor.. 47:5108-5111. 1987
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.. 47:1731-1739. 1987
Quantitative Structure-Activity Relationships: Analysis of Interactions of 2,3,7,8-Tetrachlorodibenzo-p-dioxin and 2-Substituted Analogues with Rat, Mouse, Guinea Pig, and Hamster Cytosolic Receptor1. 47:5092-5140. 1987
Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers.. 46:5406-5408. 1986
Membrane lipids and enzymes of cultured high- and low-metastatic B16 melanoma variants.. 44:3262-3269. 1984
Video time-lapse microscopy of phagocytosis and intracellular fate of crystalline nickel sulfide particles in cultured mammalian cells.. 42:2729-2735. 1982
Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.. 42:1116-1119. 1982
Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer.. 41:5121-5124. 1981
FREQUENCY OF 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR IN HUMAN-BREAST CANCER. 41:5121-5124. 1981
Duavee (R) improves metabolic health without increasing cancer risk: findings from a preclinical model of obesity and postmenopausal breast cancer. 2021
Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes. 2021
Randomized trial of 12 months of omega-3 fatty acids vs placebo during a weight loss intervention in post-menopausal women at increased risk for breast cancer 2021
Aurora kinase inhibitors cause cell death in HPV plus cells: A plausible treatment option for HPV plus cancers. 2021
Combined deacetylase and bromodomain inhibition downregulates ERCC2 and suppresses growth of metastatic colon cancer cells. 2021
Identification of pathways that enhance cell death in NOTCH1-mutant HNSCC. 2021
Abstract 21: Optimization of dosing regimens of sulindac in combination with erlotinib for small intestine and colorectal cancer prevention 2020
Abstract 3477: Dietary polyphenols as epigenetic reader' inhibitors 2020
Abstract 4106: High throughput chemical profiling of chemoresistant triple negative breast cancer 2020
Abstract 550: Determining efficacy of drug combinations identified by unbiased high throughput screening for RAS-mutated colorectal cancer 2020
Abstract PD5-01: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays in triple negative breast cancer 2020
Out-of-pocket expenditure, probability of underinsurance and health services utilization among non-elderly cancer survivors 2020
Abstract 1402: Single cell transcriptomic profiling of ex vivo tumoroid models reveal therapeutic vulnerabilities of pancreatic ductal adenocarcinoma 2019
Abstract 2171: Activatable nanodelivery of high payload gemcitabine augments therapeutic efficacy in murine breast and pancreatic cancer models 2019
Abstract 2406: A general probabilistic algorithm to predict de novo mutations in familial diseases as demonstrated in Li-Fraumeni Syndrome 2019
Abstract 3952: Localized nanodelivery combined with immunotherapy promotes curative anti-tumor responses in a murine breast cancer model 2019
Abstract 5074: Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP 2019
Abstract P6-14-03: Metastatic breast cancer alliance's patient education and access to trials: Perceptions and actions 2019
Abstract LB-069: Identification of personalized active agents in pediatric medulloblastoma through high-throughput drug screening in matching pairs of patient derived orthotopic xenograft neurosphere and monolayer cells 2018
Abstract 1661: Discovery of potent Abelson kinase inhibitors from the scaffold of pyrano[2,3-d]pyrimidin-7-one 2018
Abstract 187: Breast cancer cells exhibit enhanced proliferation, invasion, PLAU expression and chemoresistance when exposed to fluid shear stress in an innovative 3D bioreactor 2018
Abstract 4646: Pharmacogenomic screen identifies KMT2D mutations as a biomarker of sensitivity to Aurora kinase inhibition in head and neck and cervical squamous cell carcinoma 2018
Abstract 5401: Dysregulated microRNAs in aflatoxin-induced hepatocellular carcinoma: Serum miR-182 as a potential predictive biomarker 2018
Abstract B023: Identification and biochemical validation of piperlongumine as a potent therapeutic against neuroendocrine prostate cancer 2018
Abstract LB-237: Circadian dysregulation via exposure to light at night alters DNA methylation of cancer-associated genes in murine mammary tissue 2018
Abstract 1542: Identifying genetic modifiers of PTEN using the Collaborative Cross mouse panel 2017
Abstract 179: Plasma membrane lipid therapy: disruption of oncogenic Ras spatiotemporal organization by membrane-targeted dietary bioactives (MTDB) 2017
Abstract 255: Dietary amphiphilic polyphenols modulate the biophysical properties of plasma membrane organization and membrane-dependent macropinocytosis 2017
Abstract 3250: Computational drug repositioning and biochemical validation of piperlongumine as a potent therapeutic agent for neuroendocrine prostate cancer 2017
Abstract 3400: Progression of epidermal growth factor receptor (EGFR)-independent colorectal cancer 2017
Abstract 3772: A multi-scale survey to assess the impact of inflammatory diseases of the abdominal cavity and prostate cancer severity 2017
Abstract 4603: Protocol optimization combining activatable nanodelivery with immunotherapy in a murine breast cancer model 2017
Abstract LB-222: A nanoscale optical reporter implant for miRNA biomarkers in vivo 2017
Abstract A15: Progression of colorectal cancer through epidermal growth factor receptor (EGFR)-independent mechanisms 2017
Abstract 4448: Elevated levels of circulating miR-34a-5p and miR-181c-3p during cancer initiation by aflatoxin B1 2017
Abstract 465: CD44 as a potential therapeutic target and prognosis marker for glioblastoma 2016
Abstract LB-039: Genetic dissection of mechanisms underlying epidermal growth factor receptor-independent colorectal cancer development 2016
Abstract LB-052: Activatable nanodelivery combined with CpG-ODN and anti-PD-1 achieves a complete response in directly-treated and contralateral tumors in a murine breast cancer model 2016
Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study 2016
Abstract 1083: Temporal trends in microRNAs during subchronic aflatoxin dosing and modulation by the chemopreventive oleane triterpenoid, CDDO-Im 2016
Abstract P2-05-23: TWIST1 silences FOXA1 transcription to promote breast cancer progression 2016
Abstract B36: NF-kappaB-dependent and -independent roles for NIK in regulating GBM cell invasion 2015
Abstract 3742: The influence of masculinity, racism, and social support on colorectal cancer screening uptake among African American men: A systematic review 2015
Abstract 3879: Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencing 2015
Abstract 4291: An optimized therapeutic nanoparticle delivery platform of miRNA in preclinical murine models of malignancy 2015
Abstract P3-11-02: Predictors of complete pathological response to neoadjuvant chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011 2015
Abstract 1041: PTHrP(12-48) localization is intracellular and it inhibits cell proliferation and osteoclastogenesis 2015
Abstract 695: Synergistic antitumor effects of polo like kinase inhibitor volasertib in combination with ionizing radiation in glioblastoma 2015
Abstract 1536: Whole genome sequencing of high-grade treatment-nave prostate tumors 2014
Abstract SY04-02: Dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner 2014
Abstract 3744: High-throughput in vitro screening of glioma stem cell lines: Evaluation of over 350 tyrosine kinase inhibitors 2014
Abstract 4898: High content clonogenic survival assay for drug library screening identifies potent radiation sensitizers for non-small cell lung cancer 2014
Abstract 5169: Diagnostic yield of clinical tumor and germline exome sequencing for newly diagnosed children with solid tumors 2014
Early life exposure to air pollution and promoter methylation in breast tumors in the Western New York Exposures and Breast Cancer Study 2014
Abstract 1352: Epithelial-mesenchymal transition (EMT) gene variants influence epithelial ovarian cancer risk in women of European, African and Asian ancestry. 2013
Abstract 3464: CEBPD (C/EBP) acts as a tumor suppressor in hormone receptor positive breast cancer cells and may serve as biomarker to predict the need for adjuvant therapy. 2013
Abstract 3644: Variation in transmembrane transport genes influence epithelial ovarian cancer risk and histopathologic subtype. 2013
Abstract 4850: Variation in circadian rhythm genes influence epithelial ovarian cancer risk and invasiveness. 2013
Abstract A39: Multimodal imaging of blood-brain barrier disruption during brain metastatic progression in a relevant experimental mouse model 2013
Abstract P5-07-03: Gallotannins and Gallic acid From Mango Fruit (Mangifera Indica L) Suppress Breast Cancer Tumor Growth by Targeting Phosphatidylinositol3-kinase (PI3K)-Akt-NF-kB Pathway and Associated microRNAs 2012
Abstract 3592: Risk factors of prostate cancer in African American men 2012
Abstract 5430: Analysis of genome-wide DNA methylation in CCRF-CEM cells confirms hypermethylation at reported epigenetic markers of T-cell lymphoblastic leukemia and identifies novel therapeutic targets with reduced methylation upon treatment with dietary indoles 2012
Abstract LB-184: Differential effects of sulforaphane and related isothiocyanates on HDAC turnover and the DNA damage response in colon cancer cells 2012
Abstract 3296: SRC-3 is a critical mediator in the development of castration-resistant prostate cancer 2012
Abstract 702: Drug resistance and invasion in diffuse large B-cell lymphoma are mediated by Akt, 14-3-3, and Vimentin 2011
Defining two populations of prostate cancer cells with distinct molecular, biological, and tumor-propagating properties 2011
P4-16-01: Proteomic Analysis of Patient Plasma Identifies Parathyroid Hormone Related Protein (PTHrP12-48) as a Potential Biomarker of Breast Cancer Bone Metastasis. 2011
Travel distance and pattern of care for laryngeal cancer in Kentucky 2011
Abstract 18: Targeted epidermal ablation of EGFR causes local and systemic inflammation 2010
Abstract 2126: Quantitative trait locus analysis of tumor morphology in a mouse model of human colorectal cancer 2010
Abstract 276: Docosahexaenoic acid alters the spatio-temporal segregation and activation of EGF receptor 2010
Abstract 4210: Gsta4 modifies susceptibility to skin tumor development in mice and humans 2010
Abstract 5538: Enhanced tumor cytotoxicity of a combinational therapy using liposomal copper-doxorubicin, rapamycin, and ultrasound 2010
Abstract 955: n-3 polyunsaturated fatty acids promote apoptosis in oxidatively stressed transgenic mouse models 2010
Abstract 72: Metformin enhances tumor regression and reduces tumor burden in a preclinical paradigm modeling obesity's impact on postmenopausal breast cancer 2010
Dysregulated eicosanoid signaling associated with COX-2 overexpression in the BK5.COX-2 mouse model of pancreatic cancer 2009
Histone deacetylase inhibitor induces autophagy through targeting mitochondria 2009
Bub1 up-regulation and hyper-phosphorylation are major features promoting malignant transformation in SV40 Tag -induced transgenic mouse models 2006
Growth inhibitory and differentiating effects of anthocyanin-enriched fruit extracts on colon cancer cells 2006
Role of IGFBP-3 in the proliferation of MDA-MB-231 breast carcinoma cells in bone metastasis 2006
Characterization of EGFR-independent signaling pathways in ApcMin tumors 2006
Characterization of proliferative responses of rat lymphatic endothelial cells RMLEC in vitro 2006
Colonic cyclopurines induced by azoxymethane and irradiation are decreased by dietary fish oil 2006
Diverse tumor promoting agents induce epidermal Glutathione S-transferase alpha 4 (Gsta4) levels in tumor promotion resistant C57BL/6 mice 2006
Identifying resistance modifiers of azoxymethane induced colon cancer. 2006
Regulation of Stat3 gene transcription by triplex-forming oliogonucleotides in mice 2006
TPA-induced expression of the Nmes1 homolog in mouse epidermis is associated with resistance to skin tumor promotion 2006
Abstract LB-098: Antitumor studies: Design, synthesis, antitumor activity and molecular docking study of novel 2-deoxo-2-substituted-5-deazaalloxazines

CANCER RESEARCH Journal

Overview

publication venue for

Identity

International Standard Serial Number (ISSN)